The objective of the AVERROES study was to determine if apixaban 5 mg BID (2.5 mg BID in selected patients) is superior to Acetylsalicylic Acid (81 to 324 mg QD) for preventing the composite outcome of stroke or systemic embolism in patients with atrial fibrillation, and at least one additional risk factor for stroke, who have failed or are unsuitable for vitamin K antagonist therapy.

Patients received active apixaban tablets and placebo ASA tablets, or placebo apixaban tablets and active ASA tablets.

Primary endpoint:

Composite of stroke or systemic embolism.

Study Type

Interventional - Drug

Study Design

Randomized double blind, double dummy parallel arm

NO. of Countries


NO. of Sites


NO. of Participants


Study Period

2007 - 2010



Back To Top